• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

    6/11/25 5:06:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care
    Get the next $AIRS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Feinstein Adam T

    (Last) (First) (Middle)
    C/O ADAM T. FEINSTEIN
    412 WEST 15TH STREET 2ND FLOOR

    (Street)
    NEW YORK NY 10011

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Airsculpt Technologies, Inc. [ AIRS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.001 Par Value 06/09/2025 P 462,957 A $4 14,038,819 I By VSCP EBS Aggregator, L.P.
    Common Stock, $0.001 Par Value 06/09/2025 P 149,185 A $4 4,523,899 I By Vesey Street Capital Partners Healthcare Fund-A, LP
    Common Stock, $0.001 Par Value 06/09/2025 P 387,858 A $4 11,761,462 I By EBS Aggregator Blocker Holdings, LLC
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Feinstein Adam T

    (Last) (First) (Middle)
    C/O ADAM T. FEINSTEIN
    412 WEST 15TH STREET 2ND FLOOR

    (Street)
    NEW YORK NY 10011

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VSCP EBS Aggregator, L.P.

    (Last) (First) (Middle)
    C/O ADAM T. FEINSTEIN
    412 WEST 15TH STREET 2ND FLOOR

    (Street)
    NEW YORK NY 10011

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    EBS Aggregator Blocker Holdings, LLC

    (Last) (First) (Middle)
    C/O ADAM T. FEINSTEIN
    412 WEST 15TH STREET 2ND FLOOR

    (Street)
    NEW YORK NY 10011

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    /s/ Adam T. Feinstein 06/11/2025
    /s/ Adam T. Feinstein Managing Member of Vesey Street Capital Partners Healthcare GP, L.P.as general partner of VSCP EBS Aggregator, L.P. 06/11/2025
    /s/ Adam T. Feinstein Manager of EBS Aggregator Blocker Holdings, LLC 06/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AIRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIRS

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    5/14/2024$8.25 → $5.00Outperform → Market Perform
    Leerink Partners
    11/11/2022$4.00Overweight → Neutral
    Piper Sandler
    6/16/2022$17.00 → $8.50Overweight → Equal-Weight
    Morgan Stanley
    11/23/2021$18.00Outperform
    Raymond James
    11/23/2021$17.00Overweight
    Morgan Stanley
    11/23/2021$26.00Outperform
    SVB Leerink
    11/23/2021$22.00Overweight
    Piper Sandler
    More analyst ratings

    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on AirSculpt Technologies

      BTIG Research initiated coverage of AirSculpt Technologies with a rating of Neutral

      10/17/24 7:13:51 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Technologies downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded AirSculpt Technologies from Outperform to Market Perform and set a new price target of $5.00 from $8.25 previously

      5/14/24 7:53:44 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Technologies downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded AirSculpt Technologies from Overweight to Neutral and set a new price target of $4.00

      11/11/22 3:44:11 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    SEC Filings

    See more
    • AirSculpt Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

      6/11/25 4:15:43 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • SEC Form 424B5 filed by AirSculpt Technologies Inc.

      424B5 - Airsculpt Technologies, Inc. (0001870940) (Filer)

      6/9/25 5:23:32 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

      5/8/25 1:47:52 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

      4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

      6/11/25 5:06:44 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • Executive Chairman Rollins Aaron bought $7,629 worth of shares (2,118 units at $3.60), increasing direct ownership by 0.01% to 15,146,039 units (SEC Form 4)

      4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

      5/20/25 4:11:19 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Jashnani Yogesh bought $18,532 worth of shares (7,000 units at $2.65), increasing direct ownership by 2% to 464,879 units (SEC Form 4)

      4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

      5/7/25 5:56:15 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    Leadership Updates

    Live Leadership Updates

    See more
    • AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

      MIAMI BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), an industry leader and provider of premium body contouring procedures, today announced the appointment of Yogi Jashnani as Chief Executive Officer ("CEO") and a member of the Board of Directors. He succeeds Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer who will continue as Chief Financial Officer, all effective January 7, 2025. A highly-talented, results oriented executive with an accomplished career spanning more than two decades, Mr. Jashnani has architected successful transformations for public and private companies in the aesthetics

      12/17/24 6:45:00 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    Financials

    Live finance-specific insights

    See more
    • AirSculpt Technologies Reports First Quarter Fiscal 2025 Results and Full Year Guidance

      MIAMI BEACH, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the first quarter ended March 31, 2025. "We began the year reporting results in line with our expectations, and while we are early in our transformation, I am encouraged by the progress the team has made on the business imperatives we set in place at the start of the year and I remain confident that we have identified and are implementing the right actions to return to growth," stated Yogi Jashnani, Chief Executive Officer. "To this end, the first quarter saw profitability

      5/2/25 6:00:00 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Technologies Announces First Quarter Fiscal 2025 Earnings Release Date and Conference Call

      MIAMI BEACH, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2025 financial results before market open on Friday, May 2, 2025, to be followed by a conference call on the same day at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13753206 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirScul

      4/25/25 6:45:00 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Technologies Reports Fourth Quarter, and Full Year Fiscal 2024 Results

      MIAMI BEACH, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2024. "Following a challenging 2024, I am eager to help write the next chapter for AirSculpt and focus on setting a strategy, implementing business processes and developing a culture that delivers meaningful value for our shareholders," stated Yogi Jashnani, Chief Executive Officer. "AirSculpt possesses many strengths given its proprietary method, its successful track record of providing more th

      3/14/25 6:00:00 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AirSculpt Announces Closing of Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

      MIAMI BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced the closing of its previously announced underwritten public offering of 3,160,000 shares of common stock. In addition, the underwriter has exercised in full its option to purchase an additional 474,000 shares of common stock. The proceeds from the offering, after estimated expenses, are estimated to be approximately $13.8 million. Leerink Partners acted as the sole bookrunner for the offering. AirSculpt currently intends to use a majority of the net proceeds from the offering for the prepa

      6/11/25 4:05:00 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Announces Pricing of Offering of Common Stock

      MIAMI BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced the pricing of its previously announced underwritten public offering of 3,160,000 shares of common stock. AirSculpt has agreed to sell the shares to the underwriter at a price of $3.80 per share, for proceeds to the Company, before expenses, of $12.0 million. AirSculpt has also granted the underwriter a 30-day option to purchase up to 474,000 additional shares of common stock at the same price. The offering is expected to close on or about June 11, 2025, subject to customary closing conditio

      6/10/25 6:55:00 AM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • AirSculpt Announces Public Offering of Common Stock

      MIAMI BEACH, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced the launch of an underwritten public offering of 3,160,000 shares of its common stock. The underwriter will also have a 30-day option to purchase up to 474,000 additional shares of common stock. All of the shares of common stock in the offering are being sold by the Company. Vesey Street Capital Partners, L.L.C., which is affiliated with two directors and is the largest stockholder of the Company, has expressed an interest in purchasing up to $4.0 million in shares of common stock in th

      6/9/25 4:25:00 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

      4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

      6/11/25 5:06:44 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • Executive Chairman Rollins Aaron bought $7,629 worth of shares (2,118 units at $3.60), increasing direct ownership by 0.01% to 15,146,039 units (SEC Form 4)

      4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

      5/20/25 4:11:19 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • Director Chu Caroline was granted 58,594 shares, increasing direct ownership by 50% to 176,780 units (SEC Form 4)

      4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

      5/8/25 7:55:44 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care

    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AirSculpt Technologies Inc.

      SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

      11/8/24 8:42:05 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by AirSculpt Technologies Inc. (Amendment)

      SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

      2/14/24 1:11:48 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by AirSculpt Technologies Inc.

      SC 13G - Airsculpt Technologies, Inc. (0001870940) (Subject)

      4/27/23 9:49:49 PM ET
      $AIRS
      Medical/Nursing Services
      Health Care